Email:
global@GCP-ClinPlus.com
GCP ClinPlus delivered comprehensive biostatistical services for an innovative oral targeted therapy inhibiting cancer cell proliferation, specifically developed for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Our end-to-end biostatistical support accelerated the product's market approval through the NMPA and FDA Fast Track pathways, establishing a new benchmark for Chinese-developed innovative drugs in the global market.
1. Navigating Unpredictable Clinical Trial Risks
Frequent regulatory guideline updates during the boom phase of innovative drug development created significant uncertainties
Inconsistent standardization in Chinese-localized CDISC translations complicated data structure compatibility with global requirements
2. Overcoming Technical Limitations
Legacy data analysis tools inadequately supported aggressive project timelines, causing communication delays and extended delivery timelines
Sponsor demanded exceptional quality standards for result presentations, including precise graphical aesthetics and strict adherence to deadlines
1. Advanced Project Management Framework
Process & Tool Optimization: Enhanced and standardized 10+ internal workflows and tools to align perfectly with CDISC standards and client requirements
Proactive Risk Control: Conducted 40+ technical workshops to ensure ongoing compliance with rapidly evolving regulatory guidelines
Timeline Discipline: Implemented strict milestone monitoring for data query resolution and quality control submissions
2. Excellence in Service Delivery
PDCA Methodology: Deployed Plan-Do-Check-Act cycles throughout the project to continuously improve efficiency and quality
Knowledge Leadership: Compiled and published CDISC Chinese localization best practices at industry conferences, positioning GCP ClinPlus as a standards leader
3. Operational Excellence
Cross-functional Collaboration: Mobilized 62 specialists across data management, biostatistics, and programming to support 162+ IND/NDA submission components
Exceptional Resource Commitment: Dedicated 17,766+ working hours (including 1,200+ overtime hours) to ensure on-time delivery without compromising quality
Global Recognition: Supported the first fully China-developed innovative drug to receive FDA Orphan Drug Designation, enhancing international confidence in China's R&D capabilities
Regulatory Success: Secured both NMPA and FDA Fast Track status, creating a new regulatory benchmark for Chinese biopharmaceutical companies
Accelerated Approval: Achieved 2020 approval based on single-arm trial data in oncology—establishing a landmark case for accelerated approval pathways in China
Technical Excellence: Delivered zero-error, high-precision statistical reports meeting all NDA requirements within aggressive timelines
As an international CRO fully aligned with ICH standards, GCP ClinPlus delivers comprehensive clinical research services across diverse therapeutic areas. While this case highlights our success in oncology and immunology, our expertise extends to numerous fields including cell therapy, cardiovascular, neurology, rare diseases, and traditional pharmaceutical products.
Our team specializes in:
Rapidly assessing and reorganizing troubled projects
Implementing strategic recovery plans to overcome existing delays
Transforming behind-schedule studies into successful, timely completions
Our integrated approach combines regulatory expertise, quality assurance, and sophisticated project management to rescue challenged studies and help innovative therapies reach patients faster without compromising safety or efficacy.